Welcome, Guest
Username: Password: Remember me
General
  • Page:
  • 1

TOPIC: Nothing cures COPD !!!

Nothing cures COPD !!! 11 Feb 2013 11:17 #140

  • myownhedgefund
  • myownhedgefund's Avatar Topic Author
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 2713
  • Thank you received: 199
I was making some lunch and in the background I heard a commercial come on for a drug called Spriva and while they were touting the wonders of the drug they were also saying to remember, that nothing cures COPD.
This of course reminded me of the small data set from ifats that did show some nice early results in infused cells with patients with COPD.

Someday, maybe we see real advancement in treatment for this large group of patients !!!

Please Log in or Create an account to join the conversation.

Nothing cures COPD !!! 26 Feb 2013 07:24 #207

  • myownhedgefund
  • myownhedgefund's Avatar Topic Author
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 2713
  • Thank you received: 199
Hey look...Spriva mentioned again !!! LOL

Cytori Therapeutics (CYTX) has appointed Steven Kesten, MD, as Executive Vice President and Chief Medical Officer. In this role, Dr. Kesten will lead global clinical development operations and Cytori’s Medical Affairs activities.

“Dr. Kesten is a seasoned physician executive with more than 30 years of experience in medicine,” said Dr. Hedrick. “This experience includes involvement in high profile clinical trials, leading medical affairs activities, and navigating complex reimbursement environments. Dr. Kesten’s contributions will further strengthen our clinical program, starting with our cardiovascular business and extending to future therapeutic areas.”

Most recently Dr. Kesten served as Vice President and Chief Medical Officer at Uptake Medical, where he oversaw the completion of the VAPOR trial and had medical responsibility for the application that led to the CE Mark approval of Uptake Medical’s device, InterVapor®. He previously served for more than ten years at Boehringer Ingelheim, most recently as the Vice President in Medicine for Marketed Products for respiratory disease. During his tenure, Dr. Kesten was responsible for the development and execution of multiple large-scale clinical trials and took the medical lead in the global registration, branding and reimbursement of the drug Spiriva®, a $3 billion worldwide product for chronic obstructive pulmonary disease. Dr. Kesten lived in Germany for three years and is experienced in European regulatory affairs and reimbursement strategies.

In addition, Dr. Kesten held the position of medical director of the Rush Advanced Lung Disease and Lung Transplant Program at Rush Presbyterian St. Luke’s Medical Center in Chicago. Dr. Kesten received his medical degree and specialty training in internal medicine and pulmonary medicine at the University of Toronto and has more than 160 peer-reviewed publications.

Please Log in or Create an account to join the conversation.

  • Page:
  • 1
Time to create page: 0.145 seconds

Copyright Information

Copyright Fas Kuiters © 2016 young-foxes.com. All Rights Reserved.
This page is made with Joomla CMS and its various templates designed by Fas Kuiters with the excellent Themler tool.

 

 

Shared Spreadsheet Links

DOV´s Revised Projections for the Periods 2017 until 2020

Shareble link : HERE

Fas Kuiters Websites